LexaGene Announces Advancements to its Sample Preparation Cartridge for the Veterinary Market
29. März 2022 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., March 29, 2022 (GLOBE NEWSWIRE) -- LexaGene Holdings Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that has commercialized the MiQLab® System, a...
LexaGene Closes Multiple MiQLab Sales
03. Dezember 2021 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Dec. 03, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen...
LexaGene Finalizes Design of Pneumonia Panel
01. November 2021 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an...
LexaGene Completes First Stage of U.S. ARMY DEVCOM Agreement
29. Oktober 2021 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Oct. 29, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an...
LexaGene’s MiQLab™ System Selected to be a Best in Show Spotlight at the 47th Annual Industry Petcare Innovation Summit
27. Oktober 2021 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Oct. 27, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an...
LexaGene Completes Analytical Studies for FDA EUA of COVID-19 Testing
25. Oktober 2021 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Oct. 25, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a molecular diagnostics company that has commercialized an...
LexaGene Reports on Recent Veterinary Trade Shows
30. September 2021 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Sept. 30, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (OTCQB: LXXGF; TSX-V: LXG) (“LexaGene” or the “Company”), a commercial molecular diagnostics company selling a...
LexaGene Enters into Cooperative Research and Development Agreement with the United States Army’s Combat Capabilities Development Command
16. September 2021 07:45 ET
|
LexaGene Holdings Inc
BEVERLY, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- LexaGene Holdings, Inc., (TSX-V: LXG; OTCQB: LXXGF) (the “Company”), a molecular diagnostics company that develops fully automated rapid pathogen...
LexaGene’s MiQLab™ Accurately Detects Multiple Strains of Pathogenic Bacteria in Polymicrobial Samples Compared to Conventional Culture
07. September 2021 07:45 ET
|
LexaGene Holdings Inc
MiQLab detected both bacterial strains in polymicrobial samples in ~2 hoursCulture and Sensitivity Testing (C&ST) failed to detect the minor pathogen population in individual mixed samples, with...
LexaGene’s MiQLab™ System Featured at Three Key Veterinary Tradeshows
03. September 2021 07:45 ET
|
LexaGene Holdings Inc
September 7-9, WVC 93rd Annual Conference, Las Vegas, NVSeptember 12-14, International Veterinary Emergency and Critical Care, Nashville, TNSeptember 23-26, Southwest Veterinary Symposium, San...